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Identity 
Other names: CRD-BP; CRDBP; IMP-1; IMP1; 
VICKZ1; ZBP1 
HGNC (Hugo): IGF2BP1 
Location: 17q21.32 
Local order: The IGF2BP1 gene is located on the plus 
strand on chromosome 17, at 17q21.32. This gene starts
at 47074774 and ends at 47133507 bp from pter, 
encompasses 58734 bp and lies 5' of the gene 
B4GALNT2, encoding beta-1,4-N-acetyl-
galactosaminyl transferase 2. 
Note 
The IGF2BP1 gene encodes a member of the IGF-II 




There are 4 probable alternative promoters driving 
transcription of IGF2BP1 and two of them have been 
experimentally confirmed (Gu et al., 2008). The  
upstream (promoter) region contains binding sites for 
the following transcription factors: delta CREB, CREB, 
NF-kappaB1, NF-kappaB, AP-1, HNF4 alpha2, 
FOXO1a, MZF-1, Max and c-Myc. Beta-catenin/TCF4 
binding and activation of transcription has been 
experimentally confirmed (Gu et al., 2008). 
Transcription 
Two protein coding transcripts exist resulting from 
alternative splicing: 
Transcript variant 1 (NM_006546). The length of this 
transcript is 8769 nt and encompasses all 15 exons 
(exon 1: 509 bp, exon 2: 60 bp, exon 3: 48 bp, exon 4: 
51 bp, exon 5: 63 bp, exon 6: 281 bp, exon 7: 134 bp, 
exon 8: 122 bp, exon 9: 135 bp, exon 10: 122 bp, exon 
11: 119 bp, exon 12: 74 bp, exon 13: 131 bp, exon14: 
113 bp, exon 15: 6973 bp). 
Several alternative 3' ends (polyadenylation sites) exist 
at exon 15 3'-UTR (marked by flags in the figure 
above). Translation starts at +335 and ends at +2068. 
Transcript variant 2 (NM_001160423.1). It 
encompasses 8352 bp and lacks two consecutive in-
frame exons (6 and 7). 
Other spliced variants have been reported without 















The IGF2BP1 protein translated from the transcript 
variant 1 consists of 577 aa (63,48 kD) and has 2 highly 
conserved RRM motifs belonging to the RNA 
recognition motif (RRM) superfamily and 4 KH 
domains (NP_006537.3). The third and fourth KH 
domains constitute both the protein dimerization motif 
and the RNA binding domain. The four KH domains 
promote granule formation and stress granule targetin  
(Stöhr et al., 2006). Two nuclear export signals (NES) 
exist within the second and fourth KH domains 
(Nielsen et al., 2003). The KH domains have been 
implicated in the suppression of HIV-1 infectivity 
(Zhou et al., 2008). Phosphorylation sites are marked 
(Bennetzen et al., 2010; Dephoure et al., 2008). 
Phosphorylation of Tyrosine 396 prevents RNA 
binding and translation inhibition of beta-actin mRNA 
(Hüttelmaier et al., 2005). 
The IGF2BP1 protein translated from transcript 2 
variant is predicted to consist of 438 aa (48.597 kD)
and contain 2 RRM and 3 KH domains 
(NP_001153895.1). 
Expression 
IGF2BP1 is widely expressed in fetal tissues (liver, 
lung, kidney, thymus, etc), placenta and CD34+ cord 
blood cells (Nielsen et al., 1999; Ioannidis et al., 2001; 
Ioannidis et al., 2005). Postnatally it is expressed in 
ovary (oocytes and granulosa cells), in testis 
(spermatogonia), in semen (Hammer et al., 2005) and 
in intestinal crypts (Nielsen et al., 1999; Dimitriad s et 
al., 2007). It is expressed de novo in kidney, prostate, 
trachea, testis, ovarian and lung cancer, melanoma, 
mesenchymal and brain tumors. At protein level, it is 
expressed in testicular, lung and colon cancer. 
Localisation 
IGF2BP1 has been detected in the nucleus, cytoplasm, 
cytoplasmic mRNPs, granules (Nielsen et al., 2002; 
Nielsen et al., 2003). In stress granules IGF2BP1 co 
localizes with G3BP1 and TIAL1 (Stöhr et al., 2006). It 
has also been detected in lamellipodia (Yaniv et al., 
2003), growth cones and the leading edge of 
developing axons (Eom et al., 2003). 
Function 
mRNA translation: IGF2BP1 regulates translation by 
binding the 5'-UTR of the mRNA of certain genes, 
including insulin-like growth factor 2 (Nielsen et al., 
1999), and beta actin (Hüttelmaier et al., 2005). It has 
been identified in a HCV IRES-mediated translation 
complex along with EIF3C and RPS3, enhancing 
translation of the Hepatitis C virus (HCV) RNA-
replicon via the internal ribosome entry site (IRES), 
without affecting 5'cap-dependent translation (Weinlich 
et al., 2009). IGF2BP1 binds the adenine-rich 
autoregulatory sequence (ARS) of the 5'-UTR of the 
PABPC1 mRNA in collaboration with CSDE1 and 
PABPC1 proteins and causes translational repression 
(Patel and Bag, 2006; Patel et al., 2005). 
 
IGF2BP1 protein translated from transcript 1 variant. 
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mRNA stabilization: IGF2BP1 binds to the coding 
region mRNA stability determinant (CRD) of c-myc 
mRNA and protects it from endonucleolytic cleavage 
(Doyle et al.,1998; Lemm and Ross, 2002). It protects 
MDR-1 mRNAs from endonucleolytic cleavage by 
binding to a coding region element (Sparanese and Lee, 
2007). Also binds to the coding region of betaTrCP1 
mRNA and stabilizes it by disrupting miRNA-
dependent interaction with AGO2 (Noubissi et al., 
2006; Elcheva et al., 2009). Binds and stabilizes GLI1 
mRNA causing an elevation of GLI1 expression and 
transcriptional activity (Noubissi et al., 2009). 
IGF2BP1 binds to multiple elements in the 3'-UTR of 
the CD44 mRNAs and stabilizes this mRNA (Vikesaa 
et al., 2006). Binds to the 3'-UTR of Micropthalmia 
associated transcription factor mRNA and prevents the 
binding of miR-340 to its target sites, resulting in 
stabilization of the transcript, elevated expression and 
activity of this transcription factor (Goswami et al., 
2010). 
mRNA transportation: IGF2BP1 binds to the fourth 
and fifth exons of the oncofetal H19 RNA (Runge et 
al., 2000) and with ELAVL4 and G3BP to 3'-UTR of 
the neuron-specific TAU mRNA (Atlas et al., 2004; 
Atlas et al., 2007) and regulates their localization. In 
collaboration with IGF2BP2, IGF2BP1 binds to the 
conserved 54-nucleotide element in the 3'-UTR of the 
beta actin mRNA, known as the 'zip code'. IGF2BP1 
promotes the localization of the beta-actin mRNA to 
dendrites (Eom et al., 2003). IGF2BP1 may act as a 
regulator of mRNA transport to activated synapses in 
response to synaptic activity. 
Protein binding: IGF2BP1 interacts through the third 
and fourth KH domains with PABPC1 in a RNA-
independent manner (Patel and Bag, 2006) and can 
form homo- and heterodimers with IGF2BP2 or 
IGF2BP3 (Nielsen et al., 2004). It interacts with fragile 
X metal retardation protein isoform 18 (Rackham and 
Brown, 2004). It interacts with DHX9, ELAVL2, 
HNRNPA2B1, HNRNPC, HNRNPH1, HNRNPU, 
IGF2BP2, IGF2BP3, ILF2 and YBX1 (Weindensdorfer 
et al., 2009). IGF2BP1 was identified in a mRNP 
granule complex, with hnRNP A1, hnRNP A2/B1, 
hnRNP D, hnRNP L, hnRNP Q, hnRNP R, hnRNP U, 
YB1/major core protein, interleukin enhancer-binding 
factor 2 and 3, PABP1, PABP2, PABP4, nucleolin, 
RNA helicase A, a series of 40 S ribosomal proteins, 
and the nuclear cap-binding protein CBP80 (Jønson et 
al., 2007). IGF2BP1 associates with HIV-1 particles. It 
interacts (via KH3 and KH4 domains) with HIV-1 
GAG protein and diminishes viral RNA packaging, 
thwarts GAG processing to the cellular membranes, 





The identity of human IGF2BP1 over an aligned region 
in UniGene is as follows: 
- Pan troglodytes: 99.83% 
- Canis lupas familiaris: 90.93% 
- Bos taurus: 91.05% 
- Mus musculus: 89.43% 




IGF2BP1 is expressed in lung cancer and its expression 
correlates with adverse histological and clinical 
features and is an indicator of poor prognosis. 
Suppression of its expression with siRNA suppresses 
growth of NSCLC cells in vitro (Ioannidis et al., 2004; 
Kato et al., 2007). 
Ovarian cancer 
Disease 
Increased expression of IGF2BP1 mRNA is associated 
with an advanced clinical stage and poor prognosis in 
patients with ovarian cancer (Köbel et al., 2007). 
Testicular cancer 
Disease 
Detected in testicular carcinomas even in early stage 
carcinoma in situ (Hammer et al., 2005). 
Melanoma 
Disease 
IGF2BP1 is highly expressed in primary human 
malignant melanomas and melanoma cell line (Elcheva 
et al., 2008). 
Breast cancer 
Disease 
The IGF2BP1 gene is amplified in breast cancer (Doyle 
et al., 2000). Significant associations are detected 
between IGF2BP1 expression and the absence of 
estrogen receptors. IGF2BP1 collaborates with c-myc 
amplification to render tumours more aggressive 
(Ioannidis et al., 2003). Tissue specific induced 
expression in transgenic mice promotes tumor 
formation (Tessier et al., 2004). 
Colon cancer 
Disease 
IGF2BP1 is scarce or absent from normal colon but is 
over expressed in colorectal cancer. IGF2BP1 positive 
tumours associate with metastasis/recurrence and 
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Hepatocellular carcinoma 
Disease 
IGF2BP1 is detected as an autoantigen in 
hepatocellular carcinoma (Himoto et al., 2005). 
Oncogenesis 
Note 
The oncogenic action of IGF2BP1 is effected through 
the stabilization of the mRNA of oncogenes such as c-
myc, betaTrCP1, Gli and upregulation of their 
expression. IGF2BP1 expression may promote 
metastasis by shuttling requisite RNAs to the 
lamellipodia of migrating cells (Vikesaa et al., 2006; 
Vainer et al., 2008). 
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